Total glucosides of paeony (TGP) alleviates constipation and intestinal inflammation in mice induced by Sjögren's syndrome

J Ethnopharmacol. 2020 Oct 5:260:113056. doi: 10.1016/j.jep.2020.113056. Epub 2020 Jun 7.

Abstract

Ethnopharmacological relevance: Sjögren's syndrome (SS) is an autoimmune disease and can cause gastrointestinal disorders such as constipation and intestinal inflammation. As a kind of medicinal material, Paeonia lactiflora Pall has a variety of pharmacological effects, and it is also an indispensable component in many pharmaceutical preparations, which has been widely concerned by the medical and pharmaceutical circles. Total glucosides of paeony (TGP) is a mixture of biologically active compounds extracted from the root of Paeonia lactiflora Pall and has therapeutic effects on a variety of autoimmune diseases.

Aim of the study: To investigate the therapeutic effect of TGP on constipation and intestinal inflammation in mice modeled by SS, and to provide a basis for clinical research.

Materials and methods: The SS model was set up by submandibular gland (SMG) immune induction method and then treated with TGP for 24 weeks. The fecal characteristics were observed and the fecal number and moisture content were measured. Colonic pathology was observed by H&E staining. The levels of serum P substance (SP), vasoactive intestinal peptide (VIP), interleukin (IL)-1β, tumor necrosis factor (TNF)-α, nuclear factor (NF)-κB, nitric oxide (NO), and nitric oxide synthase (NOS) were determined by enzyme linked immunosorbent assay (ELISA) and microplate method, respectively. Reverse transcription polymerase chain reaction (RT-PCR) was employed to analyze the mRNA expression of c-kit and stem cell factor (SCF) in colon.

Results: Compared with the model group, the dry and rough condition of the feces was improved, and the fecal gloss, number and moisture content significantly increased after the administration of TGP capsules. Meanwhile, TGP treatment improved colonic pathological damage, inhibited the serum concentrations of NO, NOS, IL-1β, TNF-α, NF-κB and SP, increased serum VIP concentration, and up-regulated mRNA expression of SCF and c-kit in colon.

Conclusions: TGP could obviously attenuate SS-mediated constipation and intestinal inflammation in mice by acting on some intestinal motility related factors and inflammatory factors.

Keywords: Colon; Constipation; Inflammation; Sjögren's syndrome; Total glucosides of paeony.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / isolation & purification
  • Anti-Inflammatory Agents / pharmacology*
  • Colitis / immunology
  • Colitis / metabolism
  • Colitis / prevention & control*
  • Colon / drug effects*
  • Colon / immunology
  • Colon / metabolism
  • Colon / physiopathology
  • Constipation / immunology
  • Constipation / metabolism
  • Constipation / physiopathology
  • Constipation / prevention & control*
  • Defecation / drug effects*
  • Disease Models, Animal
  • Female
  • Gastrointestinal Motility / drug effects*
  • Glucosides / isolation & purification
  • Glucosides / pharmacology*
  • Inflammation Mediators / blood
  • Laxatives / isolation & purification
  • Laxatives / pharmacology*
  • Mice, Inbred C57BL
  • Paeonia* / chemistry
  • Plant Extracts / isolation & purification
  • Plant Extracts / pharmacology*
  • Proto-Oncogene Proteins c-kit / genetics
  • Proto-Oncogene Proteins c-kit / metabolism
  • Signal Transduction
  • Sjogren's Syndrome / drug therapy*
  • Sjogren's Syndrome / immunology
  • Sjogren's Syndrome / metabolism
  • Stem Cell Factor / genetics
  • Stem Cell Factor / metabolism

Substances

  • Anti-Inflammatory Agents
  • Glucosides
  • Inflammation Mediators
  • Laxatives
  • Plant Extracts
  • Stem Cell Factor
  • Proto-Oncogene Proteins c-kit